How do the results of KEYNOTE-B15/EV-304 influence your preferred treatment for cisplatin eligible MIBC?
1 Answers
Mednet Member
Medical Oncology · Northwestern University
The management of urothelial cancer has undergone major changes in the last decade.
We have seen a number of new drugs approved for relapsed BCG-refractory superficial bladder cancer. Additionally, we have seen a number of new approaches for the management of muscle-invasive bladder cancer (MIBC) or ...